Baricinix 2 is a Janus kinase (JAK) inhibitor indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more TNF antagonist therapies
Limitation of Use:
Use of Baricitinib in combination with other JAK inhibitors, biologic DMARDs, or with potent immunosuppressants such as azathioprine and cyclosporine is not recommended.
DOSAGE AND ADMINISTRATION
The recommended dose of BARICITINIB 2MG is 2 mg once daily.
BARICITINIB 2MG may be used as monotherapy or in combination with methotrexate or other DMARDs.
Anemia: Avoid initiation or interrupt BARICITINIB 2MG in patients with hemoglobin less than 8 g/dL.
Lymphopenia: Avoid initiation or interrupt BARICITINIB 2MG in patients with an Absolute Lymphocyte Count less than 500 cells/mm.
Neutropenia: Avoid initiation or interrupt BARICITINIB 2MG in patients with an Absolute Neutrophil Count less than 1000 cells/mm
Baricitinib 2mg Side Effects：
Common side effects of BARICITINIB 2MG include (these are not all of the possible side effects of BARICITINIB 2MG): • upper respiratory tract infections (common cold, • cold sores sinus infections) • shingles • nausea